Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth

CDK4/cyclin D kinase constitutes an attractive pharmacological target for development of anticancer therapeutics, in particular in KRAS-mutant lung cancer patients, who have a poor prognosis and no targeted therapy available yet. Although several ATP-competitive inhibitors of CDK4 have been develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouclier, Celine, Simon, Matthieu, Laconde, Guillaume, Pellerano, Morgan, Diot, Sebastien, Lantuejoul, Sylvie, Busser, Benoit, Vanwonterghem, Laetitia, Vollaire, Julien, Josserand, Véronique, Legrand, Baptiste, Coll, Jean-Luc, Amblard, Muriel, Hurbin, Amandine, Morris, May C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019173/
https://www.ncbi.nlm.nih.gov/pubmed/32104498
http://dx.doi.org/10.7150/thno.40971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019173/
https://www.ncbi.nlm.nih.gov/pubmed/32104498
http://dx.doi.org/10.7150/thno.40971

Ejemplares similares